Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with breast cancer: results from an interim analysis of the non-interventional study NADIR. 7. Juni 2016 Fietz, T., Kurbacher, C.M., Trarbach, T., Salat, C., Rezai, M., Lorenz, A., Niemeier, B., 2016. Oncol Res Treat 39 (suppl3)(P952), 293. doi:10.1159/000449050 Abstract First interim analysis of OTILIA, a large German non-interventional study evaluating bevacizumab-containing therapy in patients with ovarian cancer. Mustea, A., Mahner, S., Oskay-Oezcelik, G., Wimberger, P., Jungberg, S., Reichert, D., Forstbauer, H., Keller, M., Richter, R., Frank, M., Klawitter, S., Kiewitz, C., Müller,… Weiterlesen Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with Non-Hodgkin-Lymphoma (NHL): results from an interim analysis of the non-interventional study NADIR. Fietz, T., Wolff, T., Schulz, H., Sandner, R., Reichert, D., Hurtz, H.-J., Müller, J., Grebhardt, S., 2016. Oncol Res Treat, DGHO-Jahrestagung (Leipzig) 39 (suppl3)(P950), 292. Weiterlesen